Vir Biotechnology, Inc.
General ticker "VIR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $883.9M (TTM average)
Vir Biotechnology, Inc. follows the US Stock Market performance with the rate: 13.1%.
Estimated limits based on current volatility of 4.4%: low 6.04$, high 6.60$
Factors to consider:
- Total employees count: 408 (-30.5%) as of 2024
- US accounted for 15.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Net losses and need for financing, Labor/talent shortage/retention, Leadership changes and recruitment challenges, Strategic risks and growth management, Regulatory and compliance
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.57$, 11.02$]
- 2025-12-31 to 2026-12-31 estimated range: [4.70$, 11.13$]
Financial Metrics affecting the VIR estimates:
- Positive: with PPE of -1.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -44.59 <= 0.04
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 49.88 > -0.62
- Positive: Shareholder equity ratio, % of 82.24 > 64.17
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term VIR quotes
Long-term VIR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1,615.80MM | $86.18MM | $74.20MM |
| Operating Expenses | $782.73MM | $770.49MM | $661.37MM |
| Operating Income | $833.07MM | $-684.30MM | $-587.16MM |
| Non-Operating Income | $-78.79MM | $56.11MM | $64.06MM |
| R&D Expense | $474.65MM | $589.67MM | $506.50MM |
| Income(Loss) | $754.28MM | $-628.19MM | $-523.11MM |
| Taxes | $238.44MM | $-13.08MM | $-1.15MM |
| Profit(Loss)* | $515.84MM | $-615.06MM | $-521.96MM |
| Stockholders Equity | $2,077.96MM | $1,590.24MM | $1,150.38MM |
| Assets | $2,802.09MM | $1,919.06MM | $1,398.81MM |
| Operating Cash Flow | $1,663.25MM | $-778.78MM | $-446.35MM |
| Capital expenditure | $68.01MM | $21.57MM | $7.30MM |
| Investing Cash Flow | $-1,193.46MM | $164.63MM | $499.37MM |
| Financing Cash Flow | $34.76MM | $7.48MM | $4.39MM |
| Earnings Per Share** | $3.89 | $-4.59 | $-3.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.